EGFR and KRAS mutations in lung carcinomas in the Dutch population: Increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma

Cellular Oncology

Volumn 35, Issue 3, 2012, Pages 189-196

  Smits, Alexander J J ^a,b   Kummer, J Alain ^a   Hinrichs, John W J ^b,c   Herder, Gerarda J M ^a   Scheidel Jacobse, Karen C ^a   Jiwa, N Mehdi ^c   Ruijter, T Emiel G ^d   Nooijen, Peet T G A ^e   Looijen Salamon, Monica G ^f   Ligtenberg, Marjolijn J L ^f   Thunnissen, Frederik B ^g   Heideman, Daniëalle A M ^g   De Weger, Roel A ^b   Vink, Aryan ^b  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Location Alkmaar   (Netherlands)

^d RIJNSTATE HOSPITAL   (Netherlands)

^e JEROEN BOSCH HOSPITAL   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adenocarcinoma; EGFR; KRAS; Metastasis; Non small cell lung cancer; Pleural effusion

Indexed keywords

ADULT; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; COHORT ANALYSIS; CONTROLLED STUDY; EGFR GENE; EXON; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NETHERLANDS; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; PERICARDIAL EFFUSION; PLEURA EFFUSION; PLEURA METASTASIS; POPULATION GENETICS; PRIMARY TUMOR; PRIORITY JOURNAL; SOFT TISSUE METASTASIS;

ADENOCARCINOMA; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; MUTATION RATE; NEOPLASM METASTASIS; NETHERLANDS; PLEURAL EFFUSION, MALIGNANT; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84870016694     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-012-0078-4     Document Type: Article

References (33)

1. H. Linardou, I.J. Dahabreh, D. Kanaloupiti, F. Siannis, D. Bafaloukos, P. Kosmidis et al., Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced nonsmall-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 9, 962-972 (2008)
2. N.C. Bae, M.H. Chae, M.H. Lee, K.M. Kim, E.B. Lee, C.H. Kim et al., EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genet. Cytogenet. 173, 107-113 (2007) (Pubitemid 46281348)
3. B. Gao, Y. Sun, J. Zhang, Y. Ren, R. Fang, X. Han et al., Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas. J. Thorac. Oncol. 5, 1130-1135 (2010)
4. J.L. Marks, M.D. McLellan, M.F. Zakowski, A.E. Lash, Y. Kasai, S. Broderick et al., Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS One 2, e426 (2007)
5. G.J. Riely, W. Pao, D. Pham, A.R. Li, N. Rizvi, E.S. Venkatraman et al., Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treatedwith gefitinib or erlotinib. Clin. Cancer Res. 12, 839-844 (2006) (Pubitemid 43259866)
6. S.Y. Lee, M.J. Kim, G. Jin, S.S. Yoo, J.Y. Park, J.E. Choi et al., Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J. Thorac. Oncol. 5, 1734-1740 (2010)
7. A. Fassina, A. Gazziero, D. Zardo, M. Corradin, E. Aldighieri, G.P. Rossi, Detection of EGFR and KRAS mutations on transthoracic needle aspiration of lung nodules by high resolution melting analysis. J. Clin. Pathol. 62, 1096-1102 (2009)
8. S. Chiosea, Y. Shuai, K. Cieply, M.N. Nikiforova, S. Dacic, EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations. Hum. Pathol. 41, 1053-1060 (2010)
9. A. Marchetti, C. Martella, L. Felicioni, F. Barassi, S. Salvatore, A. Chella et al., EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J. Clin. Oncol. 23, 857-865 (2005) (Pubitemid 46224186)
10. R.K. Hsieh, K.H. Lim, H.T. Kuo, C.Y. Tzen,M.J. Huang, Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest 128, 317-321 (2005)
11. D.A. Heideman, F.B. Thunnissen, M. Doeleman, D. Kramer, H.M. Verheul, E.F. Smit et al., A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes. Cell. Oncol. 31, 329-333 (2009)
12. S.G. Wu, C.H. Gow, C.J. Yu, Y.L. Chang, C.H. Yang, Y.C. Hsu et al., Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. Eur. Respir. J. 32, 924-930 (2008)
13. S. Matsumoto, K. Takahashi, R. Iwakawa, Y.Matsuno, Y. Nakanishi, T. Kohno et al., Frequent EGFRmutations in brainmetastases of lung adenocarcinoma. Int. J. Cancer 119, 1491-1494 (2006) (Pubitemid 44258830)
14. C.H. Gow, Y.L. Chang, Y.C. Hsu, M.F. Tsai, C.T. Wu, C.J. Yu et al., Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann. Oncol. 20, 696-702 (2009)
15. K. Schmid, N. Oehl, F. Wrba, R. Pirker, C. Pirker, M. Filipits, EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin. Cancer Res. 15, 4554-4560 (2009)
16. R. Rosell, T. Moran, C. Queralt, R. Porta, F. Cardenal, C. Camps et al., Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361, 958-967 (2009)
17. A. Helland, H.M. Skaug, L. Kleinberg, M.L. Iversen, A.K. Rud, T. Fleischer et al., EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery. J. Thorac. Oncol. 6, 947-950 (2011)
18. H. Shigematsu, L. Lin, T. Takahashi, M. Nomura, M. Suzuki, I.I. Wistuba et al., Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst. 97, 339-346 (2005) (Pubitemid 40425952)
19. D. Kramer, F.B. Thunnissen, M.I. Gallegos-Ruiz, E.F. Smit, P.E. Postmus, C.J. Meijer et al., A fast, sensitive and accurate high resolution melting (HRM) technology-based assay to screen for common K-ras mutations. Cell. Oncol. 31, 161-167 (2009)
20. S.A. Forbes, G. Bhamra, S. Bamford, E. Dawson, C. Kok, J. Clements et al., The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr. Protoc. Hum. Genet. Chapter 10, Unit-(2008)
21. H. Sasaki, K. Okuda, O. Kawano, K. Endo, H. Yukiue,T. Yokoyama et al., Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler. Oncol. Rep. 18, 623-628 (2007)
22. S.A. Ahrendt, P.A. Decker, E.A. Alawi, Y.R. Zhu Yr, M. Sanchez-Cespedes, S.C. Yang et al., Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92, 1525-1530 (2001) (Pubitemid 32947838)
23. G.J. Riely, K.A. Politi, V.A. Miller, W. Pao, Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin. Cancer Res. 12, 7232-7241 (2006) (Pubitemid 46095394)
24. T. Takano, Y. Ohe, H. Sakamoto, K. Tsuta, Y. Matsuno, U. Tateishi et al., Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 23, 6829-6837 (2005)
25. R.S. Leidner, P. Fu, B. Clifford, A. Hamdan, C. Jin, R. Eisenberg et al., Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. J. Clin. Oncol. 27, 5620-5626 (2009)
26. C.H. Gow, C.R. Chien, Y.L. Chang, Y.H. Chiu, S.H. Kuo, J.Y. Shih et al., Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clin. Cancer Res. 14, 162-168 (2008)
27. C.H. Yang, C.J. Yu, J.Y. Shih, Y.C. Chang, F.C. Hu, M.C. Tsai et al., Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J. Clin. Oncol. 26, 2745-2753 (2008)
28. I.I. Na, J.K. Rho, Y.J. Choi, C.H. Kim, J.S. Koh, B.Y. Ryoo et al., Clinical features reflect exon sites of EGFR mutations in patients with resected non-small-cell lung cancer. J. Korean Med. Sci. 22, 393-399 (2007)
29. J. Okami, K. Taniguchi, M. Higashiyama, J. Maeda, K. Oda, N. Orita et al., Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer. Oncology 72, 234-242 (2007) (Pubitemid 351161616)
30. S. Kobayashi, T.J. Boggon, T. Dayaram, P.A. Janne, O. Kocher, M. Meyerson et al., EGFR mutation and resistance of non-smallcell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792 (2005) (Pubitemid 40271173)
31. S. Toyooka, K. Kiura, T. Mitsudomi, EGFR mutation and response of lung cancer to gefitinib. N. Engl. J. Med. 352, 2136 (2005) (Pubitemid 40664319)
32. J.Y. Wu, S.G. Wu, C.H. Yang, C.H. Gow, Y.L. Chang, C.J. Yu et al., Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin. Cancer Res. 14, 4877-4882 (2008)
33. D.A. Eberhard, B.E. Johnson, L.C. Amler, A.D. Goddard, S.L. Heldens, R.S. Herbst et al., Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23, 5900-5909 (2005)